文献速递心力衰竭与心肌病

盐皮质激素受体过度激活与射血分数保留的心力衰竭

Mineralocorticoid receptor overactivation in heart failure with preserved ejection fraction.
PubMed 文献 · Eur Heart J · 2026-08-03

本文综述射血分数保留的心力衰竭(HFpEF)的病理机制,强调盐皮质激素受体(MR)过度激活通过肾素非依赖性醛固酮增多、皮质醇失调及配体非依赖性激活等途径参与心肌肥厚、纤维化与全身炎症。文章还总结甾体类和非甾体类MR拮抗剂在HFpEF中的疗效证据,并提出早期干预MR过度激活可能延缓疾病发生与进展。

要点

  • HFpEF常见危险因素与MR过度激活密切相关,包括高龄、女性、肥胖、糖尿病和慢性肾病。
  • 螺内酯可能减少HF相关事件,非奈利酮显著降低总体恶化HF事件与心血管死亡的复合终点。
  • MR拮抗剂在提示MR过度激活的亚组中疗效与安全性总体一致,肥胖程度较高者疗效可能更明显。

核心结论

  • MR过度激活通过多种机制促进心肌肥厚、纤维化、血管重构和全身炎症,是HFpEF的重要病理生理基础。
  • 针对MR过度激活的早期治疗干预可能降低HFpEF发生和进展的风险。

研究设计与样本

  • 本文为综述,未报告系统检索范围;内容涵盖MR过度激活与HFpEF的机制通路及MR拮抗剂的临床研究证据。

主要发现

  • 螺内酯被提示可减少HFpEF患者的心衰相关事件。
  • 非奈利酮显著降低总体恶化心衰事件与心血管死亡的复合终点。
  • 在提示MR过度激活的亚组中,MRA治疗显示出总体一致的疗效与安全性。
  • 肥胖程度较高可能与MRA疗效更明显相关。
  • 醛固酮合酶抑制剂和MR调节剂正在评估用于HFpEF的预防与治疗。

关键数值与推荐

  • MR过度激活的机制包括肾素非依赖性醛固酮增多、皮质醇失调和配体非依赖性激活。
  • HFpEF特征包括高血压左室重构伴舒张功能障碍及系统性炎症驱动的内皮功能障碍。
  • 内脏脂肪组织相关代谢与促炎改变可能参与HFpEF发生。

临床怎么用

  • 临床中可考虑将MR过度激活作为HFpEF治疗靶点,尤其对合并肥胖、糖尿病或慢性肾病等危险因素的患者。
  • 现有证据支持在临床实践和试验设计中重新考虑针对MR激活的治疗策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Heart failure (HF) with preserved ejection fraction (HFpEF) is a heterogeneous syndrome encompassing hypertensive left ventricular remodelling with diastolic dysfunction and systemic inflammation-driven endothelial dysfunction, with possible contributions from visceral adipose tissue-associated metabolic and proinflammatory alterations. However, conventional key risk factors for HFpEF, including advanced age, female sex, obesity, diabetes, and chronic kidney disease, are closely associated with mineralocorticoid receptor (MR) overactivation through several under-recognized mechanisms, i.e. renin-independent aldosterone excess, cortisol dysregulation, and ligand-independent activation. MR overactivation promotes myocardial hypertrophy and fibrosis, vascular remodelling, and systemic inflammation, all of which are hallmark features of HFpEF. Among patients with HFpEF, the steroidal MR antagonist (MRA) spironolactone has been suggested to reduce the risk of HF-related events, while the non-steroidal MRA finerenone has significantly reduced the primary composite of total worsening HF events and cardiovascular death. Across subgroups suggestive of MR overactivation, MRA therapy has shown generally consistent efficacy and safety, although greater adiposity may be associated with greater MRA efficacy. Given the continuum of MR activation across HF stages, early therapeutic intervention targeting MR overactivation may mitigate the risk of HFpEF development and progression. Furthermore, aldosterone synthase inhibitors and MR modulators, which also attenuate MR overactivation, are being evaluated for HFpEF prevention and treatment. This paper presents the mechanistic pathways linking MR overactivation to HFpEF and highlights the potential benefits of mitigating MR activation for its prevention and treatment, calling for renewed consideration of treatment strategies in clinical practice and trial design.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Kobayashi, Pitt, Zannad, et al. Mineralocorticoid receptor overactivation in heart failure with preserved ejection fraction. Eur Heart J. 2026. PMID: 42543746. doi:10.1093/eurheartj/ehag578

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。